Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher"

Acta Oncol. 2013 Aug;52(6):1235. doi: 10.3109/0284186X.2013.787167. Epub 2013 Apr 25.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Lung / drug effects*
  • Neoplasms / drug therapy*
  • Pneumonia / chemically induced*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • TOR Serine-Threonine Kinases